Ingenuity Licenses Pathways Analysis Software to Avalon
News Jan 11, 2006
Ingenuity Systems and Avalon Pharmaceuticals Inc. have announced that they have entered into an agreement whereby Avalon will license Ingenuity Pathways Analysis 3.0, enhancing Avalon's drug and target discovery process.
Avalon has a focused program to harness the power of gene disruption signatures for the isolation of drugs against previously "intractable" targets.
The Ingenuity Pathways Analysis 3.0 application is being applied to the AvalonRx® platform in several selected therapeutic areas to identify biomarkers, targets, and compounds.
Ingenuity Pathways Analysis 3.0 is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
Ingenuity claims that, with Ingenuity Pathways Analysis, scientists can integrate their own biological discoveries into Ingenuity networks, providing effective computation and functional analysis.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE